A novel potent Fas agonist for selective depletion of tumor cells in hematopoietic transplants
Aimable Nahimana(University of Lausanne), Michel A. Duchosal(Scripps Health), M Schapira(University Hospital of Lausanne), Dominique Aubry(University Hospital of Lausanne), Antoine Attinger(Debiopharm (Switzerland)), Lucienne Lagopoulos(University Hospital of Lausanne), Stéphane Demotz, Keith M. Dawson, Marc Dupuis, J Tschopp(University of Lausanne), Peter Greaney
Cited by 3
Related Papers
Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009
|Cell Death and Differentiation|2008|3.3k
Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape
|Science|1996|1.3k
Transfer of human systemic lupus erythematosus in severe combined immunodeficient (SCID) mice.
|The Journal of Experimental Medicine|1990|153
Peripheral T cells undergoing superantigen-induced apoptosis in vivo express B220 and upregulate Fas and Fas ligand.
|The Journal of Experimental Medicine|1996|136
Functional expression of Fas and Fas ligand on human gut lamina propria T lymphocytes. A potential role for the acidic sphingomyelinase pathway in normal immunoregulation.
|Journal of Clinical Investigation|1996|127